Press-release for stocks related to fda for AGNPF

Prices are updated after-hours

| -95.26% | O: 21.05% H: 0.0% C: -4.78%
treatment fda fibrosis pharmaceuticals designation drug

Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF
Published: 2022-09-19 (Crawled : 12:00) - biospace.com/
AGNPF | $0.089 178.69% 75K

| -97.66% | O: -3.64% H: 4.85% C: 4.85%
treatment fda designation

Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 2b Ifenprodil Chronic Cough Study
Published: 2022-01-14 (Crawled : 15:00) - biospace.com/
AGNPF | $0.089 178.69% 75K

| -98.61% | O: 9.2% H: 0.0% C: -4.78%
fda phase 2 als phase 2b positive chronic cough

| 156.41% | O: 14515.38% H: 0.0% C: -1.95%
fda lung cancer phase 1 positive cancer phase 2

Algernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Chronic Cough Phase 2 Study
Published: 2021-10-08 (Crawled : 12:00) - biospace.com/
AGNPF | $0.089 178.69% 75K

| 42.63% | O: -7.45% H: 16.61% C: 11.3%
fda phase 2 chronic cough

Algernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Small Cell Lung Cancer Study
Published: 2021-09-22 (Crawled : 12:00) - globenewswire.com
AGNPF | $0.089 178.69% 75K

62%

38%

CSSE 4 | $0.4323 183.85% 64.77% 220M

BOF | $1.99 70.09% 41.21% 110M

ILAG | $0.51 6.03% 40.62% 1.7M

LICN | $0.941 68.04% 40.49% 15M

AMST | $3.31 65.5% 39.58% 70M

MTC | $3.615 61.38% 38.04% 9.3M

WIMI | $1.15 58.53% 36.92% 19M

AIH | $0.45 12.5% 30.92% 320K

MULN | News | $3.78 38.46% 27.78% 13M

RILY | $29.86 37.48% 27.26% 12M

Save your searches and get alerts when important news are released.